L26/P-815 Chronic PFOA exposure causes stromal fibrosis to induce premature ovarian insufficiency through MMP13 pathway
Human Reproduction · 01.07.2026 · 41 (Supplement_1)
DOI: 10.1093/humrep/deag083.1142 ↗Kurz gefasst
Fachartikel in der Zeitschrift Human Reproduction, online erschienen am 08.07.2026. Verfasst von W. Li und 5 weiteren Autor:innen.
Abstract (Originalsprache)
Study question Is serum perfluorooctanoic acid (PFOA) associated with impaired ovarian reserve and a premature ovarian insufficiency (POI)-like phenotype, and what biological pathways may underlie these effects? Summary answer Higher serum PFOA was linked to lower AMH/AFC and higher FSH, and induced POI-like changes, follicle loss, and ovarian fibrosis via ECM/MAPK pathways in mice. What is known already POI is a common reproductive endocrine disorder marked by accelerated follicle dysfunction, infertility, and long-term health consequences. Its prevalence has risen from 1% to 3.5% over the past two decades, suggesting modifiable environmental contributors beyond genetics. Per- and polyfluoroalkyl substances (PFAS), particularly perfluorooctanoic acid (PFOA), are persistent endocrine disruptors with widespread exposure despite regulatory restrictions. Epidemiological studies link PFOA to POI, but causal mechanisms remain unclear. Prior work has focused on follicular-fluid exposure to granulosa cells, which may not fully explain progressive follicle loss, highlighting the need to explore alternative pathways such as stromal remodeling and fibrosis. Study design, size, duration A human case–control analysis plus a mouse oral-gavage exposure model. Women with POI (N = 48) and controls (N = 50) were evaluated (total N = 98). Two mouse regimens were applied: 15 mg/kg/day for 14 days (high-dose) and 1.5 mg/kg/day for 28 days (low-dose). Participants/materials, setting, methods Serum PFOA was quantified by LC/MS in women and correlated with AMH, AFC, FSH, and estradiol (Spearman). Female mice received oral PFOA and were assessed for estrous cycling, ovarian indices, and AMH/FSH (ELISA). Ovarian histology (H&E/Masson) quantified follicles and fibrosis, with stromal microdissection to profile functional markers and COL I/III. Bulk RNA-seq (GO/KEGG) and molecular docking supported ECM/MAPK-related mechanisms. Main results and the role of chance In women (N = 98), serum PFOA was inversely correlated with AMH (r = −0.385, P < 0.001) and AFC (r = −0.304, P = 0.001) and positively correlated with FSH (r = 0.351, P < 0.001), while estradiol was not associated (r = 0.112, P = 0.544). In both high- and low-dose groups, PFOA increased the diestrus and metestrus fractions and reduced the relative time in proestrus and estrus, consistent with cycle prolongation and irregularity. Oral PFOA reduced ovary weight and ovary index, and induced a POI-like endocrine profile (decreased AMH and increased FSH), accompanied by decreased follicle numbers across stages and increased atresia. Masson staining and immunofluorescence demonstrated pronounced ovarian stromal fibrosis with elevated collagen deposition (COL I and COL III). To ensure the microdissected tissue represented ovarian stroma rather than granulosa cells or oocytes, qPCR of cell-type markers was performed: BMP15 (oocyte marker) and AMH/FSHR (granulosa markers) were assessed to verify minimal contamination. Transcriptomic profiling of stromal tissue further highlighted enrichment of extracellular matrix remodeling and MAPK/p38MAPK-related pathways (including KEGG MAPK signaling and ECM–receptor interaction). Docking analyses suggested plausible binding of PFOA to JUN, MAPK13, MAPK14, and MMP13 (ΔG: −4.4, −4.9, −3.4, −2.2 kcal/mol). Limitations, reasons for caution The human analysis is observational and cannot infer causality; residual confounding is possible. Mouse dosing may exceed typical environmental exposure and may limit direct human extrapolation. Further validation in independent cohorts and mechanistic perturbation studies is needed. Wider implications of the findings These findings support a link between PFOA exposure and diminished ovarian reserve and suggest stromal fibrosis with MAPK-related signaling as candidate pathways. This work reinforces the need for exposure mitigation strategies in reproductive-age women and motivates evaluation of additional PFAS substitutes for ovarian toxicity. Trial registration number No
Zitieren
APA
Li, W., Qiao, R., Guo, F., Zhang, M., Ma, Y., & Zhang, Q. (2026). L26/P-815 Chronic PFOA exposure causes stromal fibrosis to induce premature ovarian insufficiency through MMP13 pathway. Human Reproduction, 41(Supplement_1). https://doi.org/10.1093/humrep/deag083.1142
Vancouver
Li W, Qiao R, Guo F, Zhang M, Ma Y, Zhang Q. L26/P-815 Chronic PFOA exposure causes stromal fibrosis to induce premature ovarian insufficiency through MMP13 pathway. Human Reproduction. 2026;41(Supplement_1). doi:10.1093/humrep/deag083.1142
BibTeX
@article{Li2026,
author = {Li, W. and Qiao, R. and Guo, F. and Zhang, M. and Ma, Y. and Zhang, Q.},
title = {L26/P-815 Chronic PFOA exposure causes stromal fibrosis to induce premature ovarian insufficiency through MMP13 pathway},
journal = {Human Reproduction},
year = {2026},
volume = {41},
number = {Supplement_1},
doi = {10.1093/humrep/deag083.1142}
}
EUVIMED